OASIS-HT: Design of a Pharmacogenomic Dose-Finding Study
- 5 October 2005
- journal article
- research article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 6 (7) , 756-775
Abstract
Experimental evidence and observations in humans strongly support an interactive role of mutated α-adducin, sodium (Na+)/potassium (K+)-adenosine triphosphatase (ATPase) activity and endogenous ouabain in Na+ homeostasis and the pathogenesis of hypertension. The Ouabain and Adducin for Specific Intervention on Sodium in HyperTension (OASIS-HT) trial is an early Phase II dose-finding study, which will be conducted across 39 European centers. Following a run-in period of 4 weeks without treatment, eligible patients will be randomized to one of five oral doses of rostafuroxin consisting of 0.05, 0.15, 0.5, 1.5, or 5.0 mg/day. Each dose will be compared to a placebo in a double-blind crossover experiment with balanced randomization. Treatment will be initiated with the active drug and continued with placebo or vice versa. Each double-blind period will last 5 weeks. The primary end point is the reduction in systolic blood pressure defined as the average of three clinic readings with the patient in the sitting ...Keywords
This publication has 14 references indexed in Scilit:
- Impact of Treating Blood Pressure2005
- Organ Hypertrophic Signaling within Caveolae Membrane Subdomains Triggered by Ouabain and Antagonized by PST 2238Journal of Biological Chemistry, 2004
- Hypertension Prevalence and Stroke Mortality Across PopulationsJAMA, 2003
- A Role for Lipid Shells in Targeting Proteins to Caveolae, Rafts, and Other Lipid DomainsScience, 2002
- Endogenous cardiac glycosides, a new class of steroid hormonesEuropean Journal of Biochemistry, 2002
- Residual Lifetime Risk for Developing Hypertension in Middle-aged Women and MenJAMA, 2002
- Identification and chromosomal localization of ecogenetic components of electrolyte excretionJournal Of Hypertension, 2002
- Genetic mechanisms underlying the regulation of urinary sodium excretion and arterial blood pressure: the role of adducinActa Physiologica Scandinavica, 2000
- PST 2238: A New Antihypertensive Compound that Modulates Na+,K+‐ATPase and Antagonizes the Pressor Effect of OLFCardiovascular Drug Reviews, 1999
- Clinical trials with ambulatory blood pressure monitoring: fewer patients needed?The Lancet, 1994